CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 10, 2018
Result type: Reports
Project Number: SR0474-000
Product Line: Common Drug Review

Generic Name: ticagrelor

Brand Name: Brilinta

Manufacturer: AstraZeneca Canada Inc

Indications: Prevention of atherothrombotic events with history of myocardial infarction

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: August 25, 2016

Recommendation Type: Reimburse with clinical criteria and/or conditions